Jupiter Neurosciences Inc (JUNS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.28+0.61%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · JUNS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
JUNS — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-08-28
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 27, 2026, Jupiter Neurosciences, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff had determined to delist the Company’s common stock from The Nasdaq Capital Market. As previously notified by the Staff on February 26, 2026, the market va…
Why it matters: Fixing compliance issues would help Jupiter's stock and boost investor trust.
Supportive ifJupiter reports it has fixed its Nasdaq compliance issues.
Worry ifThere are reports of ongoing non-compliance with Nasdaq rules without a fix.
Why it matters: Progress in this trial is key for Jupiter's growth strategy. Positive results could boost investor confidence.
Supportive ifThe company shares positive interim results from the Phase IIa trial.
Worry ifThe company reports delays or negative results from the Phase IIa trial.
Why it matters: Completing the ALA-002 deal would boost Jupiter's work in psychedelic therapies. This could help its market position.
Supportive ifA definitive agreement is signed for the exclusive U.S. rights to ALA-002.
Worry ifThe agreement is not finalized within 90 days of the term sheet signing.
Why it matters: Compliance is critical for maintaining the company's stock listing. Failure to comply could lead to delisting.
Worry ifManagement shares a plan to fix compliance issues with Nasdaq.
Less concerning ifNo progress or more delays in fixing compliance issues are reported.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$365 on $10,000 · ±3.7% | How much price usually moves either way. |
| Bad day | $1,289 loss on $10,000 · 12.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,759 loss on $10,000 · 97.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: If revenue growth in the health care sector picks up, it may benefit Jupiter Neurosciences. This could signal a better environment for the company.
Supportive ifHealth care revenue growth accelerates back toward 10% or higher.
Worry ifRevenue growth keeps slowing down below current levels.
Why it matters: New licensing deals could boost revenue and validate the company's growth strategy.
Supportive ifThe company shares a licensing deal for a new product with a big partner.
Worry ifNo new licensing deals are announced in the next quarter.
Why it matters: How Jupiter uses the $2 million from the recent offering can show its financial health.
Watch forJupiter shares a plan for using the $2 million raised from the offering.
Also watch forNo clear plan is communicated for the use of funds raised.
Why it matters: Changes in leaders can change company plans. Stability matters for investors.
Watch forNo more changes in leaders happen. This shows stability in leadership.
Also watch forMore big leaders leave or change jobs.
Why it matters: FDA approval would support Jupiter's main program and could bring in big money.
Supportive ifJupiter gets FDA approval for JOTROL in its Phase IIa trial for Parkinson's.
Worry ifThe FDA denies approval or delays the decision on JOTROL.
Why it matters: Stabilizing the stock price is crucial for compliance with Nasdaq listing rules.
Supportive ifStock price remains above $1 for at least 10 consecutive trading days post-split.
Worry ifStock price falls below $1 within 30 days after the reverse split.
Why it matters: A good licensing deal would support the growth plan and boost revenue.
Supportive ifThey announced a licensing deal for ALA-002. This is with PharmAla or another partner.
Worry ifNo progress on licensing deals or news of a failed agreement.
Why it matters: This split aims to raise the stock price to meet Nasdaq listing requirements. If successful, it may stabilize investor confidence.
Supportive ifThe stock trades above $1.00 on a post-split basis after August 7, 2026.
Worry ifThe stock remains below $1.00 on a post-split basis after August 7, 2026.
Why it matters: The result could affect the company's chance to get rights to a key product.
Worry ifThe lawsuit ends well, allowing the company to get ALA-002 rights.
Less concerning ifThe lawsuit ends badly, blocking the company from getting ALA-002 rights.
Why it matters: This offering is important for funding operations and cash flow. A successful close can help liquidity.
Supportive ifThe offering closed successfully. It raised the full $2 million as planned.
Worry ifThe offering fails to close or raises significantly less than $2 million.
Why it matters: The reverse stock split aims to raise the share price to meet Nasdaq rules. Compliance is crucial for continued trading.
Supportive ifJupiter's stock price has stayed above $1 for 30 trading days after the split.
Worry ifThe stock price falls below $1 for 30 consecutive trading days after the split.
Why it matters: Managing losses is key for long-term success. Better management shows stronger financial health.
Worry ifOperating losses drop a lot from last quarter. This shows better cash flow management.
Less concerning ifOperating losses go up or stay the same. This shows ongoing financial problems.
Why it matters: Progress on ALA-002 could enhance Jupiter's pipeline and market position. Delays or setbacks could hinder growth.
Watch forJupiter has a clear deal for ALA-002. It has clear terms and timelines.
Also watch forNo news or bad updates about the ALA-002 licensing agreement in the next quarter.